🚨 Mankind Pharma strengthens its diabetes portfolio! 💉📈

Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical for: 🔹 Insulin Degludec 🔹 Insulin Degludec + Aspart Combination 🎯 Why does it matter? The partnership further strengthens Mankind Pharma’s presence in the diabetes and injectable therapies segment in India. With chronic diseases becoming an increasingly important growth area, the addition of these insulin products could help Mankind expand its treatment portfolio and strengthen its position in the injectable diabetes market. 📊 AFS Trading Edge: This is a strategic portfolio expansion rather than an immediate financial trigger. Investors may watch how quickly these products are commercialised and their potential contribution to Mankind Pharma’s chronic therapy growth. 💬 What’s your view on MANKIND Pharma? ⚠️ Disclaimer: For educational and informational purposes only. Not investment advice.